跳到主要內容

很遺憾,我們無法支援你的瀏覽器。如果可以,請升級到新版本,或使用 Mozilla Firefox、Microsoft Edge、Google Chrome 或 Safari 14 或更新版本。如果無法升級,而且需要支援,請將你的回饋寄給我們。

我們衷心感謝你對這個新體驗的回饋。告訴我們你的想法(打開新的分頁/視窗)

Elsevier
與我們共同出版

Versus Arthritis

Elsevier has established a funding body agreement with Versus Arthritis(打開新的分頁/視窗) to help authors publishing in Elsevier journals comply and to facilitate a successful implementation of their policy. Details about how to comply are outlined below.

Agreement

Versus Arthritis requires grantees, from the 1st January 2007, to pursue open access publishing and are required to submit an electronic copy of the final manuscript of their research papers to PubMed Central (PMC) and PMC’s linked sister repository Europe PubMed Central (Europe PMC) within six months of publication.

Versus Arthritis-funded authors are free to choose the gold open access option offered by Elsevier. Authors can comply by publishing in either an Elsevier open access journal or in a subscription journal with an open access option. This includes journals published by The Lancet.

Gold open access

To provide open access, a publication fee needs to be met for each article published open access. For information about specific open access publication fees, please refer to the individual journal homepage and guide for authors. Versus Arthritis will meet these costs only if the author’s institution is unable to.

Upon publication, Elsevier will supply the final published article to Europe PMC on the author’s behalf. This will then be automatically mirrored on the PMC site. All articles published open access have permitted reuse which is determined by the author's choice of user license.

Green open access

Versus Arthritis-funded authors who do not have funds available for gold open access can self-archive their accepted manuscript on Europe PMC after the embargo period for their specific journal has expired. Posted accepted author manuscripts must include a link back to the original and final published articles.

Help and support